Azevedo FAC, et al. Equal number of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. Journal of Comparative Neurology 2009. 513:532–541.
National Health and Nutrition Examination Survey (NHANES) 1999–2002. Centers for Disease Control and Prevention. In: Mean Body Weight, Height, and Body Mass Index United States 1960-2002.
Dunn SE, et al. Sex-based differences in multiple sclerosis (MS): Part II: Rising incidence of multiple sclerosis in women and the vulnerability of men to progression of this disease. Curr Top Behav Neurosci 2015;26:57–86.
Brown JW, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019;321(2):175–187.
Kappos L, et al. Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the phase III OPERA I and OPERA II studies. Poster presented at: the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 10–12 October 2018; Berlin, Germany. Poster P547.
Trojano M, et al. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci 2003;24(Suppl. 5):S268–S270.
Tedeholm H, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler 2013;19(6):765–774.
Lizarraga AA, et al. Multiple sclerosis in 2019: predicting progression. Lancet Neurol 2020;19(1):12–14.
Wiendl W and Meuth SG. Pharmacological approaches to delaying disability progression in patients with multiple sclerosis. Drugs 2015;75:947–77.
Cinar BP and Yorgun YG. What we learned from the history of multiple sclerosis measurement: expanded disability status scale. Noro Psikiyatr Ars 2018;55(Suppl 1):S69–75.
Stankiewicz JM, et al. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2020;7:e636.
Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 2013;10:97–105.
Brownlee WJ, et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet 2017;389:1336–46.
Schulz D, et al. Cognition in the early stages of multiple sclerosis. J Neurol 2006;253:1002–10.
White CP, et al. Invisible and visible symptoms of multiple sclerosis: Which are more predictive of health distress? J Neurosci Nurs 2008;40:85–95.
Kasser SL, et al. Symptom variability, affect and physical activity in ambulatory persons with multiple sclerosis: Understanding patterns and time-bound relationships. Disabil Health J 2017;10:207–13.
Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handb Clin Neurol 2014;122:269–90.
Murphy KL, et al. Multiple sclerosis: Perspectives in treatment and pathogenesis, Chapter 4. 2017.
Braley TJ and Chervin RD. Fatigue in multiple sclerosis: Mechanisms, evaluation, and treatment. Sleep 2010;33:1061–7.
Beiske AG, et al. Pain and sensory complaints in multiple sclerosis. Eur J Neurol 2004;11:479–82.
Davis SL, et al. Thermoregulatory dysfunction in multiple sclerosis. Handb Clin Neurol 2018;157:701–14.
Oreja-Guevara C, et al. Cognitive dysfunctions and assessments in multiple sclerosis. Frontier Neurol 2019;10:(581)1–9.
Feenaughty L, et al. Speech and pause characteristics in multiple sclerosis: A preliminary stuy of speakers with high and low neuropsychological test performance. Clin Linguist Phon 2013;27:134–51.
Merson RM and Rolnick MI. Speech-language pathology and dysphagia in multiple sclerosis. Phys Med Rehabil Clin N Am 1998;9:631–41.
De Pauw A, et al. Dysphagia in multiple sclerosis. Clin Neurol Neurosurg 2002;104:345–51.
Koch M, et al. Tremor in multiple sclerosis. J Neurol 2007;254:133–45.
Schmidt EZ, et al. Sexuality in multiple sclerosis. J Neural Transm 2005;112;1201–11.
Fletcher SG, et al. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol 2009;6:96–107.
Sa MJ. Psychological aspects of multiple sclerosis. ClinNeurol Neurosurg 2008;110;868–77.
Löffler LAK, et al. Emotional dysfunctions in neurodegenerative diseases. J Comp Neurol 2016;524:1727–43.
Mahadeva A, et al. Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large university hospital. Am J Clin Exp Immunol 2014;3:57–67.
Hodge BH. The use of symptom diaries in outpatient care. Fam Pract Manag 2013;20:24–28.
Gümüş, H. Fatigue can be objectively measured in multiple sclerosis. Arch Neuropsychiatry 2018;55(Suppl 1):S76−79.
Joy JE, et al. Institute of Medicine. Multiple sclerosis: Current status and strategies for the future. Washington, DC: The National Academies Press. 2001;177–240.
van Kessel K, et al. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med 2008;70:205–13.
Shaygannejad V, et al. Comparison of the effect of aspiring and amantadine for the treatment of fatigue in multiple sclerosis: A randomized, blinded, crossover study. Neurol Res 2012;34:854–8.
Thomas PW, et al. Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev 2006;1:CD004431.
Sumowski JF, et al. Cognition in multiple sclerosis. Neurology 2018;90:278–88.
Perez-Martin MY, et al. Efficacy of short cognitive training program in patients with multiple sclerosis. Neuropsych Dis Treat 2017;13:245–52.
Jonkman LE, et al. Gray matter correlates of cognitive performance differ between relapsing-remitting and primary-progressive multiple sclerosis. PLoS One 2015;10:e0129380.
Adriana ID, et al. Management of diplopia. Romanian J Ophthalmol 2017;61:166–70.
Jasse L, et al. Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler 2013;19:1618–26.
Serra A, et al. Eye movement abnormalities in multiple sclerosis: pathogenesis, modeling, and treatment. Front Neurol 2018;9:31.
Niestroy A, et al. Neuro-ophthalmologic aspects of multiple sclerosis: Using eye movements as a clinical and experimental tool. Clin Ophthalmol 2007;1:267–72.
MS Society of Canada. Exercise and Physical Activity. https://mssociety.ca/hot-topics/exercise-and-physical-activity 1/12. Accessed August 2020.
Hebert JR, et al. Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upgright postural control: A randomized controlled trial. Phys Ther 2011;91:1166–83.
Hebert JR, et al. Efficacy of balance and eye-movement and eye-movement exercises for person with multiple sclerosis. Neurology 2018;27;90:e797–807.
Carling A, et al. Balance exercise facilitates everyday life for people with multiple sclerosis: A qualitative study. Physiother Res Int 2018;23:e1728.
Carling A, et al. CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled piloty study. Mult Scler 2017;23:1394–404.
Cohen ET, et al. Feasibility and impact of an 8-week integrative yoga program in people with moderate multiple sclerosis-related disability. Int J MS Care 2017;19:30–39.
Brichetto G, et al. The effect of Nintendo® Wii® on balance in people with multiple sclerosis: a pilot randomized control study. Mult Scler J 2013;19:1219–21.
Prosperini L, et al. Home-based balance training using the Wii balance board: A randomized, crossover pilot study in multiple sclerosis. Neurorehabil Neural Repair 2013;27:516–25.
Ozkul C, et al. Effect of immersive virtual reality on balance, mobility, and fatigue in patients with multiple sclerosis: A single-blinded randomized controlled trial. Eur J Integr Med 2020;35:101092.
Maggio MG, et al. Virtual reality in multiple sclerosis rehabilitation: A review on cognitive and motor outcomes. J Clin Neurosci 2019;65:106–11.
Frohman EM, et al. Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult Scler J 2003;9:250–55.
Truini A, et al. A mechanism-based classification of pain in multiple sclerosis. J Neurol 2013;260:351–67.
Zadeh AR, et al. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2. Int J Physiol Pathophysiol Pharmacol 2019;11:105–14.
Monro R, et al. Disc extrusions and bulges in nonspecific low back pain and sciatica: Exploratory randomised controlled trial comparing yoga therapy and normal medical treatment. J Back Musculoskelet Rehabil 2015;28:383–92.
Stefano GD, et al. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain 2019;20:20.
Shayestehazar M, et al. A survey of severity and distribution of musculoskeletal pain in multiple sclerosis patients; a cross-sectional study. Arch Bone Jt Surg 2015;3:114–18.
O’Connor AB, et al. Pain associated with multiple sclerosis: Systemic review and proposed classification. Pain 2008;137:96–111.
Adamec I, et al. Erythromelalgia as a manifestation of autonomic nervous ystem involvement in multiple sclerosis. Mult Scler Relat Disord 2016;8:1–3.
Halabchi F, et al. Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations. BMC Neurol 2017;17:185.
Powell DJH, et al. Tracking daily fatigue fluctuations in multiple sclerosis: ecological momentary assessment provides unique insights. J Behav Med 2017;40:772–83.
Schumacher GA, et al. Problems of experimental trails of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965;122:552–68.
Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 2015;5:e00362.
Lovblad KO, et al. MR imaging in multiple sclerosis: Review and recommendations for current practice. AJNR Am J Neuroradiol 2010;31:983–89.
Chiappa KH. Pattern-shift visual, brainstem auditory and short-latency somatosensory evoked potentials in multiple sclerosis. Neurology 1980;30:110–23.
Engelborghs S, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst) 2017;8:111–126.
Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302.
Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73.
Medina LD, et al. Patient-reported outcomes in multiple sclerosis: Validation of the quality of life in neurological disorders (Neuro-QoL™) short forms. Mult Scler J Exp Transl Clin 2019:5:1–11.
Learmonth YC, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 2013;13:37.
Institute for Quality and Efficiency in Health Care (IQWiG). What happens during a neurological examination? Available at: https://www.ncbi.nlm.nih.gov/books/NBK348940/. Accessed June 2020.
Ontario’s MRI and CT Expert Panel. Ontario Best Practice Guidelines for Managing the Flow of Patients Requiring an MRI or CT Examination. Available at: https://collections.ola.org/mon/23006/292809.pdf. Accessed July 2020.
Paty DW, et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:662–7.
Giovannoni G, et al. Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord 2016;9(Suppl 1):S5–48.
Stankiewicz JM, et al. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2020;7:e636.
Cohen BA, et al. Therapy optimization in multiple sclerosis: A cohort study of therapy adherence and risk of relapse. Mult Scler Relat Disord 2015;4:75–82.
Hupperts R, et al. The STAR study: A real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis. Clin Ther 2014;36:1946–57.
Carling A, et al. Balance exercise facilitates everyday life for people with multiple sclerosis: A qualitative study. Physiother Res Int 2018;23:e1728.
Carling A, et al. CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled piloty study. Mult Scler J 2017;23:1394–404.
Hebert JR, et al. Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upgright postural control: A randomized controlled trial. Neurology 2018;90:e797–807.
Hebert JR, et al. Efficacy of balance and eye-movement and eye-movement exercises for person with multiple sclerosis. Phys Ther 2011;91:1166–83.
Carling A, et al. CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled piloty study. Mult Scler J 2017 (Appendix);23:1394–404.
Nilsagård YE, et al. Balance exercise program reduced falls in people with multiple sclerosis: A single-group, pretest-posttest trial. Arch Phys Med Rehabil 2014;95:2428–34.
Tryfonos C, et al. Dietary supplements on controlling multiple sclerosis symptoms and relapses: Current clinical evidence and future perspectives. Medicines 2019;6:95.
Sand IK, et al. The role of diet in multiple sclerosis: Mechanistic connections and current evidence. Curr Nutr Rep 2018;7:150–60.
Evans E, et al. An overview of the current state of evidence for the role of specific diets in multiple sclerosis. Mult Scler Relat Disord 2019;36:101393.
Chenard CA, et al. Nutrient composition comparison between the low saturated fat Swank diet for multiple sclerosis and healthy U.S.-style eating pattern. Nutrients 2019;11:616.
Wahls T, et al. Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial. Trials 2018;19:309.
Yadav V, et al. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial. Mult Scler Relat Disord 2016;9:80–90.
Sand IK, et al. Randomized-controlled trial of a modified Mediterranean dietary program for multiple sclerosis: A pilot study. Mult Scler Relat Disord 2019;36:101403.
McKay KA, et al. Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. Mult Scler J 2016;22:685–93.
Murphy R, et al. Neuropsychiatric syndromes of multiple sclerosis. J Neurol Neurosurg Psychiatry 2017;88:697–708.
Quesnel S and Feinstein A. Multiple sclerosis and alcohol: A study of problem drinking. Mult Scler 2004;10:197–201.
Leslie M, et al. Patterns in workplace accommodations for people with multiple sclerosis to overcome cognitive and other disease-related limitations. Neuro Rehabilitation 2015;37:425–36.
Kasser SL, et al. Symptom variability, affect and physical activity in ambulatory persons with multiple sclerosis: Understanding patterns and time-bound relationships. Disabil Health J 2017;10:207–13.
Powell DJH, et al. Tracking daily fatigue fluctuations in multiple sclerosis: ecological momentary assessment provides unique insights. J Behav Med 2017;40:772–83.
Foley FW, et al. Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. Mult Scler 2001;7:417–21.
Schmidt EZ, et al. Sexuality in multiple sclerosis. J Neural Transm 2005;112:1201–11.
Domingo S, et al. Factors associated with sexual dysfunction in individuals with multiple sclerosis. Int J MS Care 2018;20:191–7.
Balsamo R, et al. Increased risk of erectile dysfunction in men with multiple sclerosis: an Italian cross-sectional study. Cent European J Urol 2017;70:289–95.
Döring A, et al. Exercise in multiple sclerosis – an integral component of disease management. EPMA J 2011;3:2.
Sa MJ. Psychological aspects of multiple sclerosis. Clin Neurol Neurosurg 2008;110:868–77.
Koch T, et al. Constructions of sexuality for women living with multiple sclerosis. J Adv Nurs 2002;39:137–45.
Dobson R, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol 2019;19:106–14.
Marrie RA, et al. Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. BMC Res Notes 2017;10:619–625.
Chwastiak LA and Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am 2007;30:803–817.
Hind D, et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: A systemic review and meta-analysis. BMC Psychiatry 2014;14:5.
Kiropoulos LA, et al. A pilot randomized controlled trial of a tailored cognitive behvaioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis. BMC Psychiatry 2016;16:435.
Henry A, et al. Anxiety and depression in patients with multiple sclerosis: The mediating effects of perceived social support. Mult Scler Relat Disord 2019;27:46–51.
Freeman D, et al. The effects of improving sleep on mental health (OASIS): A randomised controlled trial with mediation analysis. Lancet Psychiatry 2017;4:749–58.
Magnavita N and Garbarino S. Sleep, health and wellness at work: A scoping review. Int J Environ Res Public Health 2017;14:1347.
Freeman J, et al. “A non-person to the rest of the world”: Experiences of social isolation amongst severely impaired people with multiple sclerosis. Disabil Rehabil 2019;18:1–9.
MS Society of Canada. Friendly Visiting. https://mssociety.ca/support-services/friendly-visiting. Accessed July 2020.
Fasczewski KS, et al. I ride for MS: The impact of bike MS participation on motivation for physical activity in individuals with multiple sclerosis. Disabil Health J 2020;13:100853.
Shavazi MA, et al. Online social support for patients with multiple sclerosis: A thematic analysis of messages posted to a virtual support community. Int J Community Based Nurs Midwifery 2016;4:188–98.